Maze Therapeutics (MAZE) Total Non-Current Liabilities (2024 - 2026)

Maze Therapeutics (MAZE) has 3 years of Total Non-Current Liabilities data on file, last reported at $77.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 95.19% year-over-year to $77.6 million; the trailing twelve-month figure through Mar 2026 stood at $77.6 million (up 95.19% YoY), and the FY2025 full-year result was $41.1 million, down 3.75% from the prior year.
• Total Non-Current Liabilities improved to $77.6 million in Q1 2026, from $41.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $77.6 million in Q1 2026 to a low of $39.8 million in Q1 2025.
• A 3-year average of $47.1 million and a median of $41.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities fell 3.75% in 2025 and surged 95.19% in 2026, its largest moves.
• Tracing MAZE's Total Non-Current Liabilities over 3 years: stood at $42.7 million in 2024, then declined by 3.75% to $41.1 million in 2025, then soared by 89.01% to $77.6 million in 2026.
• Business Quant data shows MAZE's Total Non-Current Liabilities at $77.6 million in Q1 2026, $41.1 million in Q4 2025, and $41.5 million in Q3 2025.